CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009. The Phase 1 clinical proof-of-concept data on AP24534 in patients with resistant and refractory chronic myeloid leukemia (CML) will be presented by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia at the M.D. Anderson Cancer Center.
